Hippocampal Neuronal Loss in Infant Macaques Orally Infected with Virulent Simian Immunodeficiency Virus (SIV)

Heather Carryl 1, Koen K. A. Van Rompay 2, Kristina De Paris 3 and Mark W. Burke 1,*

1 Department of Physiology and Biophysics, Howard University, Washington, DC 20059, USA; heather.m.carryl@bison.howard.edu
2 California National Primate Research Center, University of California Davis, Davis, CA 95616, USA; kkvanrompay@ucdavis.edu
3 Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA; abelk@med.unc.edu
* Correspondence: mark.burke@howard.edu; Tel.: +1-202-806-7959

Academic Editor: Jaime H. Vera Rojas
Received: 27 February 2017; Accepted: 5 April 2017; Published: 10 April 2017

Abstract: The neurological impact of Human Immunodeficiency Virus (HIV) on children includes loss of brain growth, motor abnormalities and cognitive dysfunction. Despite early antiretroviral treatment (ART) intervention to suppress viral load, neurological consequences of perinatal HIV-1 infection persist. Utilizing the pediatric simian immunodeficiency virus (SIV) infection model, we tested the hypothesis that early-life SIV infection depletes neuronal population in the hippocampus. A total of 22 ART-naïve infant rhesus macaques (Macaca mulatta) from previous studies were retrospectively analyzed. Infant macaques were either intravenously (IV) inoculated with highly virulent SIVmac251 at ~1 week of age and monitored for 6–10 weeks, or orally challenged with SIVmac251 from week 9 of age onwards with a monitoring period of 10–23 weeks post-infection (19–34 weeks of age), and SIV-uninfected controls were euthanized at 16–17 weeks of age. We have previously reported that the IV SIVmac251-infected neonatal macaques (Group 1) displayed a 42% neuronal reduction throughout the hippocampal cornu ammonis (CA) fields. The orally-infected infant macaques displayed a 75% neuronal reduction in the CA1 region compared to controls and 54% fewer neurons than IV SIV infants. The CA2 region showed a similar pattern, with a 67% reduction between orally-infected SIV subjects and controls and a 40% difference between IV-and orally-infected SIV groups. In the CA3 region, there were no significant differences between these groups, however both SIV-infected groups had significantly fewer pyramidal neurons than control subjects. There was no correlation between plasma viral load and neuronal populations in any of the CA fields. The loss of hippocampal neurons may contribute to the rapid neurocognitive decline associated with pediatric HIV infection. While each subfield showed vulnerability to SIV infection, the CA1 and CA2 subregions demonstrated a potentially enhanced vulnerability to pediatric SIV infection. These data underscore the need for early diagnosis and treatment, including therapeutics targeting the central nervous system (CNS).

Keywords: pediatric human immunodeficiency virus (HIV); hippocampus; design-based stereology; non-human primate; simian immunodeficiency virus (SIV)

1. Introduction

Globally, there are over 3.2 million children under the age of 15 currently living with human immunodeficiency virus (HIV), with an estimated one new diagnosis every 2 min [1,2].
Mother-to-child-transmission (MTCT) via pregnancy, delivery or breast-feeding accounts for 15%–25% of new infections [3]. Due to the success of antiretroviral therapy (ART) for pregnant HIV-infected women, perinatal HIV-infection has been drastically reduced. In the United States, less than 200 babies are infected with HIV annually, due to the use of ART and the avoidance of breastfeeding [4]. In contrast, in under-resourced parts of the world (e.g., Sub-Saharan Africa), ART access still varies widely from country to country [5], and exclusive breastfeeding is necessary to reduce the risk of mortality due to malnutrition or non-HIV-1 illnesses such as respiratory infections and diarrhea [6–8]. Therefore, about 15% of HIV MTCT cases now occur as a result of breastfeeding [3]. Furthermore, even during ART [9], HIV-1 can persist in breastmilk. Although ART reduces the risk of MTCT of HIV in utero and peri-partum, adequate access and adherence to ART throughout the period of breastfeeding [10,11], mixed feeding/breastfeeding practices, and undiagnosed acute HIV infection of breast-feeding mothers, limit its effectiveness [12–14]; accordingly, in resource-poor areas, HIV MTCT rates remain high [15]. Another success of ART has been the increased rate of survival of HIV-infected children [16–18]. The survival of these HIV-infected infants into adolescence and adulthood poses a unique set challenges [17,19,20], as these HIV-1 positive children present with a high prevalence of cognitive and neurodevelopmental deficits [21–23].

The neurological impact of HIV-1 infection includes loss of brain growth, motor abnormalities and cognitive dysfunction [24]. Data suggests a high prevalence of encephalopathy, hyperreflexia, delayed milestones, quadriaparesis, spasticity, and microcephaly as a result of perinatal HIV-1 infection [25]. In ART-naive children, high viral load at 6 months of age was associated with a more severe neurodevelopmental dysfunction at 12 months compared to children with lower viral load [26]. A similar pattern has been reported following a course of a 48-week ART treatment [27]. Poor cognitive performance and reduced cortical gray matter volume in perinatally HIV-infected adolescents was also associated with higher peak viral load [28]. Despite the ability of early ART intervention to partially alleviate neurological consequences of perinatal HIV-1 infection, deficits persist even after viral load suppression [22,27,29,30]. Diffusion tensor imaging has been indicative of reduced radial diffusivity, which is suggestive of demyelination [31]. This finding is consistent with scarce reports of multiple-sclerosis-like disorders in HIV-1-infected children [32]. There are notable differences between HIV-infected children and adults. HIV-associated dementia, a commonly occurring neurological disorder in HIV-infected adults, is not typically observed in HIV-infected children. While HIV has not been shown to infect neurons, cognitive impairments consistent with pathological evidence of neuronal damage, such as synaptic loss and dendritic simplification, have been reported [33]. In adult subjects, elevations in cerebrospinal fluid and low molecular weight neurofilament core chains (CSF NFL) have been suggested to serve as a sensitive surrogate marker of neuronal damage, supported also by chronic changes to white matter in various other neurodegenerative diseases, such as Alzheimer’s [34]. However, CSF NFL levels are elevated in early and later stages of HIV-1 infection in adults with and without neurocognitive impairment [35,36]. CSF NFL levels also decrease with ART initiation and increase with ART interruption [37]. Analogous data are currently missing for the pediatric HIV-1 population.

Animal models may provide us with the opportunity to elucidate the neurological effects of pediatric infection [38]. Small animal models such as rats and mice are an accessible and practical substitute method of investigating neuropathogenic mechanisms of pediatric HIV-1; but there are a few noted limitations with rodent models. One obvious limitation is that rats and mice are not the natural hosts of HIV-1 and are not susceptible to HIV-1 infection, therefore they do not develop the disease [39]. Trans-activator of transcription (Tat)/Envelope glycoprotein (gp120) intracranial administration in rodents has been used to define certain aspects of neuronal damage related to pediatric HIV-1 infection [40,41]. Rodent models have also shown that gp120 and Tat1-72 are involved in the neuropathophysiology of HIV-1 infection, with notable susceptibility of the hippocampus to the neurotoxic cascade of HIV-1 proteins [40,42]. The administration of Tat1-72 was found to impair spatial memory in adolescence [40]. However, neonatal intra-hippocampal gp120 administration
transitorily alters sensory-motor function [43,44]. Design based stereology demonstrated that neonatal intrahippocampal Tat$_{1-72}$ and gp120 administration resulted in detrimental and regionally selective cell loss within the hippocampus [40]. The protein gp120 was found to reduce the neuronal population within CA2 and CA3 regions of the neonatal hippocampus while intrahippocampal Tat administration reduced neuronal populations in the CA2/3 subfields and the hilus of the dentate gyrus [40].

Additional research findings supported the hypothesis that Tat plays a significant role in pediatric HIV-1 neuropathogenesis and the overall psychological deterioration that is observed in HIV-1 infected children [42]. Results from in vitro cell culture studies indicate that the release of Tat occurs when the rate of cell death is low (as seen during infection), or when cell death is absent (as seen after transfection), and Tat expression is high [45]. In the former study, the highest expression of Tat was observed 48 hours post-transfection with 5%–10% of transfected cells expressing Tat. Results implied that cell growth requires a lower concentration of extracellular Tat than the transactivating effect [45]. A Tat concentration of 100 ng/mL or higher did not produce any growth stimulation, however at concentrations of 0.05 to 50 ng/mL, with peak activity at 0.1 to 1 ng/mL, growth stimulation was observed [45]. Although Tat has been shown to be a part of the neuropathology in perinatal HIV-1 infection, the question whether neuropathology is related to viral load remains unanswered. In adults, neuronal loss can be related to viral load, however, a similar link has not been established in children who experience HIV pathogenesis at a time of neuronal development.

The simian immunodeficiency virus (SIV) infection model in macaques offers a valid alternative because SIV and HIV-1 have similar pathogenesis, including infection of CD4+ T cells and macrophages, immune suppression, disease progression, neurological complications in juvenile and adult primates, and routes of transmission [46]. MTCT of SIV can occur by the same routes in monkeys and humans [47]. In a vertical infection model in pigtailed macaques (Macaca nemestrina), offspring of dams that were intravenously (IV)-inoculated with HIV-2287 during the third trimester displayed significant motor and cognitive delays that were correlated with cluster of differentiation 4 (CD4+) T lymphocyte cell counts at birth [48]. We have previously shown that neonatal rhesus macaques infected with SIVmac251 (IV) showed significant neuronal reductions in the hippocampus, loss of immature neurons and gross demyelination [38,49]. Here, we expand on these data and investigate the effects of oral SIVmac251 infection at nine weeks of age, simulating oral HIV-1 acquisition by breastfeeding human infants, on hippocampal neuronal populations.

2. Materials and Methods

2.1. Subjects

The brain samples used in the current study were all collected as part of previously conducted studies [50–53]. The infant rhesus macaques (Macaca mulatta) in those former studies were nursery-reared in pairs at the California National Primate Research Center (CNPRC) in accordance to American Association for Accreditation of Laboratory Animal Care Standards, with all protocols being approved by the UC Davis Institutional Animal Care and Use Committee. All procedures were performed under ketamine-HCl anesthesia (10 mg/kg i.m.; Parke-Davis, Morris Plains, NC).

The 22 infant rhesus macaques consisted of SIVmac251 IV-inoculated neonates (n = 3) with a monitoring time of 6–10 weeks (hippocampal neuronal counts for this group were previously reported; see [49]). Infant macaques in Groups 2A-C were part of a vaccine study [50,51] and received a weekly oral (PO) low-dose SIVmac251 inoculation regimen (5000 tissue culture infective dose (TCID) 50 per dose) starting at ~week 9 of age until infected; then infants were monitored for 10–23 weeks of infection (Table 1). It should be noted that the animals in Groups 2B and 2C had received different SIV vaccine regimens prior to oral SIV challenge (Table 1) [50,51]. Blood samples were drawn on a weekly basis for the PO groups and plasma SIV levels were analyzed [50,51]. Infants in Group 3 represented SIV-naïve control infant macaques (n = 4) that were euthanized between 16–17 weeks of age.
Table 1. Characteristics of subjects. SIV: simian immunodeficiency virus

| Group | Subject ID | Gender | Vaccine          | Age of SIV Infection | Age at Euthanasia | Total Infection Period | Plasma SIV Ribonucleic Acid (RNA) (Copies/mL)* |
|-------|------------|--------|------------------|----------------------|-------------------|------------------------|-----------------------------------------------|
| 1     | 41622      | M      | none             | 1 week               | 10 weeks          | 9 weeks                | 160,000,000                                  |
| 1     | 41614      | F      | none             | 1 week               | 7 weeks           | 7 weeks                | 240,000,000                                  |
| 1     | 41615      | F      | none             | 1 week               | 10 weeks          | 10 weeks               | 650,000,000                                  |
| 2A    | 42376      | F      | none             | 9 weeks              | 21 weeks          | 12 weeks               | 5,800,000                                    |
| 2A    | 42380      | F      | none             | 17 weeks             | 27 weeks          | 10 weeks               | 6,400,000                                    |
| 2A    | 42386      | F      | none             | 10 weeks             | 22 weeks          | 12 weeks               | 380,000                                      |
| 2A    | 42388      | F      | none             | 13 weeks             | 25 weeks          | 12 weeks               | 46,000,000                                   |
| 2B    | 42944      | M      | Mtb-SIV/MVA-SIV  | 9 weeks              | 33 weeks          | 24 weeks               | 170,000                                      |
| 2B    | 42958      | F      | Mtb-SIV/MVA-SIV  | 15 weeks             | 33 weeks          | 18 weeks               | 6,000,000                                    |
| 2B    | 42949      | M      | Mtb-SIV/MVA-SIV  | 9 weeks              | 21 weeks          | 12 weeks               | 18,000,000                                   |
| 2B    | 42899      | F      | Mtb-SIV/MVA-SIV  | 9 weeks              | 20 weeks          | 11 weeks               | 84,000,000                                   |
| 2B    | 42929      | F      | Mtb-SIV/MVA-SIV  | 10 weeks             | 20 weeks          | 10 weeks               | 99,000,000                                   |
| 2B    | 42906      | F      | Mtb-SIV/MVA-SIV  | 9 weeks              | 22 weeks          | 13 weeks               | 73,000,000                                   |
| 2B    | 42937      | M      | Mtb-SIV/MVA-SIV  | 9 weeks              | 21 weeks          | 12 weeks               | 15,000,000                                   |
| 2C    | 42925      | F      | Mtb-SIV/Mtb-SIV  | 10 weeks             | 22 weeks          | 12 weeks               | 4,700,000                                    |
| 2C    | 42943      | M      | Mtb-SIV/Mtb-SIV  | 10 weeks             | 21 weeks          | 11 weeks               | 9,900,000                                    |
| 2C    | 42950      | M      | Mtb-SIV/Mtb-SIV  | 9 weeks              | 19 weeks          | 10 weeks               | 77,000,000                                   |
| 2C    | 42918      | M      | Mtb-SIV/Mtb-SIV  | 19 weeks             | 34 weeks          | 15 weeks               | 860,000                                      |
| 3     | 40967      | F      | None             | N/A                  | 15 wks            | N/A                    | N/A                                           |
| 3     | 40929      | M      | None             | N/A                  | 16 wks            | N/A                    | N/A                                           |
| 3     | 41656      | F      | None             | N/A                  | 16 wks            | N/A                    | N/A                                           |
| 3     | 41660      | F      | None             | N/A                  | 16 wks            | N/A                    | N/A                                           |

* Plasma and cerebrospinal fluid (CSF) SIV RNA levels at time of euthanasia. Group 2 was exposed, starting at 9 weeks of age, once weekly to SIVmac251 by the oral route until infection was verified [50,51]. 1 Jensen et al., 2013 [53], 2 Jensen et al., 2016 [50], 3 Jensen et al., 2017 [51], 4 Jensen et al., 2013 [53]. Mtb-SIV: *Mycobacterium tuberculosis*-SIV vaccine, MVA-SIV: Modified vaccinia virus Ankara-SIV.
2.2. Brain Preservation and Histology

Upon euthanasia, brains were extracted, post-fixed in 10% buffered formalin phosphate, blocked into 1-cm slabs in the coronal plane, cryoprotected in 30% buffered sucrose, and frozen at \(-80^\circ\text{C}\) until further processing. Ten parallel series of coronal sections (50 \(\mu\text{m}\)) were obtained from each animal, the first series being Nissl stained with cresyl-violet for design-based stereology, with the remaining sections placed in antigen preserve for future studies [49].

Systematic sections through the hippocampus were Nissl stained and hippocampal pyramidal neurons were quantified using design-based stereology. Although there is an age variance between the groups, hippocampal neuronal populations through the CA fields has been shown to be stable from birth through at least two years of age [54,55]. SIVmac251 was obtained from the Analytical and Resource Core at CNPRC. Plasma viral loads were quantified by real-time reverse transcription-polymerase chain reaction (RT-PCR) [50,56].

2.3. Design-Based Stereology

Total estimation of the pyramidal neuronal population of the hippocampus cornu ammonis fields (CA1–3) was achieved using the optical fractionator method. Sampling parameters are similar to previously described methods [49] where the topography (4x objective) and superimposed counting frames (dissectors 16,000 \(\mu\text{m}^3\); plan fluor oil-immersion 100x numerical aperture (N.A.) = 1.3) were generated through the MicroBrightField Stereoinvestigator program (Williston, VT, USA). The stereological parameters are the same as previously used for Group 1 [49] where every 20th section was selected, a standard scan x-y grid was employed (500 \(\mu\text{m}\) × 500 \(\mu\text{m}\), 250 \(\mu\text{m}\) × 250 \(\mu\text{m}\), and 350 \(\mu\text{m}\) × 350 \(\mu\text{m}\) for CA1, CA2 and CA3, respectively), and the total estimation of pyramidal neuronal numbers (N) was calculated by the following equation:

\[
N = ssf^1 \times asf^1 \times tsf^1 \times \sum Q^- \]

where ssf is the section-sampling fraction, asf is the area-sampling fraction, tsf is the thickness-sampling fraction, and \(\sum Q^-\) is total number of objects of interest counted. The average coefficient of error (CE) for total number of neurons was determined to assess reliability of measurement was less than 0.12 for all subjects.

2.4. Statistical Analysis

Due to the small group sizes, statistical differences were determined only between two groups at a time applying both one-tailed [49] and two-tailed non-parametric Mann–Whitney \(U\) test of significance using the GraphPad Prism V7, and InStat3 programs (La Jolla, California, CA, USA). Correlation analyses between viremia and neuronal data were performed using the Spearman Rank test. Significance was determined as \(p < 0.05\). Viral loads were log transformed and then calculated as area under the curve (AUC) as a way to express overall exposure to avoid acute peaks or multiple peaks in viremia from carrying a relatively larger weight (i.e., skewing the data) than for example if a subject has no peaks but a persistent intermediate viremia.

3. Results

We have previously reported that IV SIVmac251-infected infants (Group 1) displayed a 42% neuronal reduction throughout the hippocampal CA fields [49]. Here, we show that orally SIVmac251-infected infants (Group 2A) subjects showed a significant neuronal reduction compared to SIV-naïve controls in all three CA regions \((p = 0.0286;\) Figures 1 and 2). It should be noted though that the duration of SIV infection in Group 2 animals was slightly longer (10–12 weeks) compared to Group 1 SIV-infected macaques (7–10 weeks). Vaccinated and orally SIV-challenged infant macaques in Groups 2B and 2C also displayed a significant neuronal reduction in all three CA regions compared to controls (Figure 2). In regions CA1 and CA3, these neuronal reductions
of Group 2B and Group 2C animals were comparable to those observed in non-vaccinated orally SIV-infected macaques of Group 2A (Figure 2). However, in the CA2 region, the neuronal reduction of infant macaques that had received two doses of the *Mycobacterium tuberculosis* (Mt)b-SIV vaccine prior to SIV infection had an even more severe neuronal reduction than non-vaccinated SIV-infected Group 2 macaques (Figure 2).

**Figure 1.** Reduced hippocampal neuronal populations: Compared to controls, Group 3 (A,B), intravenous (IV) SIV-infected neonatal macaques, Group 1, (C,D) displayed a 42% neuronal reduction throughout the hippocampal cornu ammonis (CA) fields. The orally-infected infant macaques Group 2B (E,F) and Group 2A (G,H) displayed a 70% neuronal reduction compared to controls and 47% fewer neurons than Group 1 infants. Graphs represent combined data across the different CA subfields. Magnifications A, C, E, G 1.25x (scale bar = 5 mm), and 20x B, D, F, H (scale bar = 200 μm). * p = 0.029, ** p = 0.005, *** p = 0.0005. One-tailed test between G3 and G1 [49] all other comparisons were two-tailed tests.

**Figure 2.** Reduced hippocampal neuronal populations and volumes. Groups 2A–C display significantly lower neuronal populations compared to Group 3. Volume differences were restricted to the cornus ammonis (CA)1 and CA2 subfields. * p values reflect differences between each of the treated groups (G2A–C and G3) and the simian immunodeficiency virus-naïve (SIV-naïve) control group (G1). * p = 0.029, ** p = 0.006 except # p = 0.03 which is a comparison between Groups 2A and 2C; bar in the middle of the data points represents mean. One-tailed test between G3 and G1 [49] all other comparisons were two-tailed tests.

Volume differences were found only in the CA1 and CA2, but not the CA3 region between the various groups (Figure 2). Both CA1 and CA2 volumes were significantly lower in Groups 1 and
2A–C compared to controls (Group 2) (Figure 2). The volume in infant macaques orally infected with SIVmac251 (Group 2A) was comparable to that observed in Group 2B and Group 2C infants that were vaccinated prior to SIV infection (Figure 2). There was a significant correlation between volume and neuronal population (Figure 3).

The changes in neuronal frequencies and volumes between SIV-naïve and SIV-infected animals were not directly correlated to plasma viremia at the time of euthanasia (Figures 4 and 5). Similar results were obtained when we tested for a correlation between CSF viremia and neuronal frequencies and volumes. As previous studies have shown that pathogenesis outcome is dependent on peak and set-point viremia [57,58], we also tested for a potential correlation between acute and early chronic viremia, as assessed by area-under-the-curve analysis (AUC), with neuronal changes. The degree of neuronal frequency reduction in SIV-infected macaques was not associated with acute, chronic or terminal plasma viremia (Figure 4). Likewise, the volume of the subregions was not correlated with acute, chronic or terminal plasma viremia (Figure 5).

![Figure 3. Neuronal population and volume correlation. There was a significant correlation between neuronal populations and volume in the cornu ammonis (CA) subfield 1 ($p = 0.0011$), CA2 ($p < 0.0001$) and CA3 ($p < 0.0062$) hippocampal fields.](image3)

![Figure 4. Neuronal population correlation. Despite a naturally occurring biological variance in viral loads, there was a lack of correlation between neuronal populations and plasma viral loads. AUC: area under the curve. SIV: simian immunodeficiency virus, Mtb-SIV: Mycobacterium tuberculosis-SIV vaccine, MVA-SIV: Modified vaccinia virus Ankara-SIV, CA: cornu ammonis](image4)
4. Discussion

We previously reported significant pyramidal neuronal loss in the CA1–3 fields of the hippocampus following IV inoculation with SIVmac251 within 72 h after birth with an average infection time of 8.3 weeks [49]. Here, we expanded on these data and tested the effect of oral SIV infection on neuronal damage. The oral route of SIV infection better represents HIV-1 acquisition by breastfeeding, the most common route of new mother-to-child transmissions of HIV-1. Furthermore, the age period of 9–23 weeks is more representative of the time of breastfeeding or mixed feeding practices in the clinical setting [13,14].

Our data suggests a particular vulnerability of the CA1 and CA2 region of the hippocampus. While both IV and PO SIV-infected infant macaques displayed significant reductions in pyramidal neuronal populations in the CA1-3 fields compared to controls, this effect appeared to be even more pronounced in the orally-infected infants compared to the perinatally IV-infected subjects. However, this difference was not significant and should not be over-interpreted as infants in these two groups differed not only in age at the time and route of SIV infection, but also in the duration of SIV infection. Thus, future studies should determine whether increased viral exposure time is associated with a progressive neuronal loss.

Studies of neonatal rodent models of intracranial HIV-1 tat antigen administration support clinical evidence that the neurons of the hippocampus, and hippocampal neurogenesis, are specifically susceptible to the neurotoxic cascade of HIV-1 proteins [40]. Upon intracranial injections of tat and gp-120 in neonatal rats, there is a reduction of neuronal populations in the CA1, CA2 and CA3 fields, delays in eye opening and reflex development, and altered prepulse inhibition, which are correlated to a decline in spatial memory [40,41]. In the current investigation, we examined a narrow parameter of hippocampal integrity, neuronal population and volume. With the decreased volumes of the CA1–2 regions and the reduced neuronal population in CA1–3 in all SIV-infected infants (Groups 1-2A–C), it would be expected that changes in neural circuitry extend beyond the hippocampus. Clinical data indicates significant deficits in working memory and executive functioning [28,59], which would indicate a disrupted hippocampal-prefrontal circuitry [60–62].
Much of pre-existing clinical research focuses on global cortical changes and the basal ganglia [23,31,63], but there is increasing evidence of HIV-1 related toxicity in the hippocampus [49]. Previously, neural atrophy of the hippocampus has been reported in young adult monkeys following SIV infection [64]. CA1 pyramidal neurons are probably the most studied class of neuron in the brain, and better understood from a structural and functional standpoint compared to other types of neurons in the hippocampus [65]. This is due to relative ease of obtaining intracellular recordings and field potential recordings from these regions [65]. Despite our findings of a decrease in hippocampal neurons of SIV-infected subjects, a direct connection between neuronal populations and viral load in plasma or CSF at the time of brain collection could not be established.

Clinical studies have shown that HIV RNA levels are extremely high during infancy and early childhood, in comparison to adults [66]. A study found a trend in the mean HIV-1 RNA load rising from low values (<10,000 copies/mL) at birth, to extremely high (>100,000 copies/mL) within the first 24 months of life, and then decreasing very slowly until the end of those 24 months [67]. This same study compared the viral load of infants with early (in utero transmission) vs. perinatal infection and discovered significantly varying median HIV-1 RNA values during the early months of life. At birth these values were 10,800 copies/mL, and less than 400 copies/mL; and after one month of life these values were 716,000 copies/mL and 100,000 copies/mL; with peak values of 780,000 copies/mL and 243,000 copies/mL, respectively [67]. Data from a perinatal cohort demonstrated a strong connection between high HIV RNA viral load during early infancy and poor clinical outcome, and also found that children with a higher viral load experienced rapid progression of the disease compared to children with lower loads [67]. Similar correlations between plasma viral RNA levels and disease-free survival have also been described in SIV-infected infant macaques [68,69].

Although HIV-1 has not been shown to infect neurons, there is evidence that the virus exerts its actions indirectly on neurons [70]. There is also evidence that HIV proteins are responsible for disrupting ion homeostasis and depolarizing neurons; while other proteins are restricted to neurons to disrupt neuronal membranes or induce apoptosis of the proteins [71]. Indirect neurotoxicity of HIV may involve the activation of glial cells, which have shown to result in the production and release of inflammatory cytokines like tumor necrosis factor (TNF)-alpha [70,72]. Our finding that infant macaques in Group 2C had the most severe neuronal reduction in CA2 is consistent with this conclusion. We have previously shown that vaccination with Mtb-SIV caused persistent systemic immune activation prior to and post-SIV infection [51]. Although the prior study did not analyze brain inflammation, mycobacteria-induced immune activation was persistent and systemic, and thus, could have affected the brain as well [51]. Astrocytes, microglia and macrophages are significant HIV-1 targets in the brain and research suggests that indirect mechanisms could, in part, account for severe neuronal damage observed in HIV-positive patients [73–75].

5. Conclusions

The loss of hippocampal neurons may contribute to the rapid neurocognitive decline associated with pediatric HIV infection. While each subfield showed vulnerability to SIV infection, the CA1 and CA2 subregions demonstrated a potentially increased vulnerability to SIV infection. These data underscore the need for early and continued ART as well as the development of therapeutics targeting the CNS [38].

Acknowledgments: This project was funded by District of Columbia Center for AIDS Research (P30AI087714), Latham Trust Foundation Grant, and R03MH107261 to M.W.B.; 1R01DE019064 (NIH/NIDCR) and 1R01DE022285 (NIH/NIDCR) to K.D.P.; and the Office of Research Infrastructure Programs/OD (P51OD011107) to the California National Primate Research Center. We thank Kebreten Manaye, Howard University, for the use of her MicroBrightField Stereology system.

Author Contributions: The study was designed by H.C., M.W.B., K.V.R. and K.D.P. K.D.P. and K.V.R. designed and supervised the conduct of animal studies; M.W.B. designed and supervised the anatomical and histological studies; and H.C. and M.W.B. performed the neuroanatomical and biological studies. The manuscript was written by H.C. and M.W.B. and reviewed by all authors.
Conflicts of Interest: The authors declare no conflict of interest.

References

1. The Joint United Nations Programme on HIV/AIDS (UNAIDS). Unaids fact sheet 2014; The Joint United Nations Programme on HIV/AIDS: Geneva, Switzerland, 2014.
2. UNAIDS/UNICEF/WHO/UNFPA. Children and Aids Fifth Stocktaking Report. Available online: http://www.unaids.org/en/targetsandcommitments/eliminatingnewhivinfectionamongchildren/ (accessed on 27 November 2016).
3. UNICEF. HIV and Infant Feeding. Available online: https://www.unicef.org/programme/breastfeeding/hiv.htm (accessed on 21 December 2016).
4. AIDS. HIV Prevention Preventing Mother-to-Child Transmission of HIV. Available online: https://aidsinfo.nih.gov/education-materials/fact-sheets/20/50/preventing-mother-to-child-transmission-of-hiv (accessed on 1 January 2017).
5. McIntyre, J. Antiretrovirals for Reducing the Risk of Mother-to-Child Transmission of HIV Infection: Rhl Commentary; World Health Organization: Geneva, Switzerland, 2007.
6. Zash, R.M.; Shapiro, R.L.; Leidner, J.; Wester, C.; McAdam, A.J.; Hodinka, R.L.; Thior, I.; Moffat, C.; Makhema, J.; McIntosh, K.; et al. The aetiology of diarrhoea, pneumonia and respiratory colonization of HIV-exposed infants randomized to breast- or formula-feeding. Paediatr. Int. Child Health 2016, 36, 189–197. [CrossRef] [PubMed]
7. Becquet, R.; Ekouevi, D.K.; Arrive, E.; Stringer, J.S.; Meda, N.; Chaix, M.L.; Treluyer, J.M.; Leroy, V.; Rouzioux, C.; Blanche, S.; et al. Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: Towards the elimination of mother-to-child transmission of hiv-1 in resource-limited settings. Clin. Infect. Dis. 2009, 49, 1936–1945. [CrossRef] [PubMed]
8. Rollins, N.C.; Ndirangu, J.; Bland, R.M.; Coutsoudis, A.; Coovadia, H.M.; Newell, M.L. Exclusive breastfeeding, diarrhoeal morbidity and all-cause mortality in infants of HIV-infected and hiv uninfected mothers: An intervention cohort study in kwazulu natal, south africa. PLoS ONE 2013, 8, e81307. [CrossRef] [PubMed]
9. Van de Perre, P.; Rubbo, P.A.; Viljoen, J.; Nagot, N.; Tylleskar, T.; Lepage, P.; Vendrell, J.P.; Tuavillon, E. HIV-1 reservoirs in breast milk and challenges to elimination of breast-feeding transmission of hiv-1. Sci. Transl. Med. 2012, 4, 143sr143. [CrossRef] [PubMed]
10. Ngoma, M.S.; Misir, A.; Mutale, W.; Rampakakis, E.; Sampalis, J.S.; Elong, A.; Chisele, S.; Mwale, A.; Mwansa, J.K.; Mumba, S.; et al. Efficacy of who recommendation for continued breastfeeding and maternal cart for prevention of perinatal and postnatal hiv transmission in zambia. J. Int. AIDS Soc. 2015, 18, 19352. [CrossRef] [PubMed]
11. Hoffmann, I.C.; Santos, W.M.; Padoin, S.M.; Barros, S.M. A five-year review of vertical HIV transmission in a specialized service: Cross-sectional study. Sao Paulo Med. J. 2016, 134, 508–512. [CrossRef] [PubMed]
12. Coovadia, H.M.; Bland, R.M. Preserving breastfeeding practice through the hiv pandemic. Trop. Med. Int. Health 2007, 12, 1116–1133. [CrossRef] [PubMed]
13. Coovadia, H.M.; Rollins, N.C.; Bland, R.M.; Little, K.; Coutsoudis, A.; Bennish, M.L.; Newell, M.L. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: An intervention cohort study. Lancet 2007, 369, 1107–1116. [CrossRef]
14. Becquet, R.; Ekouevi, D.K.; Menan, H.; Amani-Bosse, C.; Bequet, L.; Viho, I.; Dabis, F.; Timite-Konan, M.; Leroy, V. ANRS 1201/1202 Ditrame Plus Study Group. Early mixed feeding and breastfeeding beyond 6 months increase the risk of postnatal hiv transmission: Anrs 1201/1202 ditrame plus, abidjan, cote d’ivoire. Prev. Med. 2008, 47, 27–33. [CrossRef] [PubMed]
15. Manji, K.P.; Duggan, C.; Liu, E.; Bosch, R.; Kisenge, R.; Aboud, S.; Kupka, R.; Fawzi, W.W. Exclusive breast-feeding protects against mother-to-child transmission of HIV-1 through 12 months of age in tanzania. J. Trop. Pediatr. 2016, 62, 301–307. [CrossRef] [PubMed]
16. Brady, M.T.; Oleske, J.M.; Williams, P.L.; Elgie, C.; Mofenson, L.M.; Dankner, W.M.; Van Dyke, R.B. Pediatric AIDS Clinical Trials Group219/219c Team. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the haart era. J. Acquir. Immune Defic. Syndr. 2010, 53, 86–94. [CrossRef] [PubMed]
17. Mofenson, L.M.; Cotton, M.F. The challenges of success: Adolescents with perinatal HIV infection. *J. Int. AIDS Soc.* 2013, 16, 18650. [CrossRef] [PubMed]
18. Mofenson, L.M. Prevention of mother-to-child HIV transmission: Can we meet the goal of global elimination of new pediatric infections? *Curr. Opin. HIV AIDS* 2013, 8, 443–446. [CrossRef] [PubMed]
19. Dowshen, N.; D’Angelo, L. Health care transition for youth living with HIV/AIDS. *Pediatrics* 2011, 128, 762–771. [CrossRef] [PubMed]
20. Sohn, A.H.; Hazra, R. The changing epidemiology of the global paediatric hiv epidemic: Keeping track of perinatally HIV-infected adolescents. *J. Int. AIDS Soc.* 2013, 16, 18555. [CrossRef] [PubMed]
21. MacDonell, K.; Naar-King, S.; Huszti, H.; Belzer, M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. *AIDS Behav.* 2013, 17, 86–93. [CrossRef] [PubMed]
22. van Arnhem, L.A.; Bunders, M.J.; Scherpbier, H.J.; Majoie, C.B.; Reneman, L.; Frinking, O.; Poll-The, B.T.; Kuipers, T.W.; Pajkrt, D. Neurologic abnormalities in HIV-1 infected children in the era of combination antiretroviral therapy. *PLoS ONE* 2013, 8, e64398. [CrossRef] [PubMed]
23. Van Rie, A.; Harrington, P.R.; Dow, A.; Robertson, K. Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: A global perspective. *Eur. J. Paediatr. Neurol.* 2007, 11, 1–9. [CrossRef] [PubMed]
24. Mitchell, W. Neurological and developmental effects of HIV and AIDS in children and adolescents. *Ment. Retard. Dev. Disabil. Res. Rev.* 2001, 7, 211–216. [CrossRef] [PubMed]
25. Walker, S.Y.; Pierre, R.B.; Christie, C.D.; Chang, S.M. Neurocognitive function in HIV-positive children in a developing country. *Int. J. Infect. Dis.* 2013, 17, e862–e867. [CrossRef] [PubMed]
26. Pollack, H.; Kuchuk, A.; Cowan, L.; Hacimamutoglu, S.; Glasberg, H.; David, R.; Krasinski, K.; Borkowsky, W.; Oberfield, S. Neurodevelopment, growth, and viral load in HIV-infected infants. *Brain Behav. Immun.* 1996, 10, 298–312. [CrossRef] [PubMed]
27. Jeremy, R.J.; Kim, S.; Nozyce, M.; Nachman, S.; McIntosh, K.; Pelton, S.I.; Yogev, R.; Wiznia, A.; Johnson, G.M.; Krogstad, P.; et al. Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. *Pediatrics* 2005, 115, 380–387. [CrossRef] [PubMed]
28. Lewis-de Los Angeles, C.P.; Alpert, K.I.; Williams, P.L.; Malee, K.; Huo, Y.; Csernansky, J.G.; Yogev, R.; Van Dyke, R.B.; Sowell, E.R.; Wang, L.; et al. Deformed subcortical structures are related to past HIV disease severity in youth with perinatally acquired hiv infection. *J. Pediatr. Infect. Dis. Soc.* 2016, 5, S6–S14. [CrossRef] [PubMed]
29. Donald, K.A.; Hoare, J.; Eley, B.; Wilmshurst, J.M. Neurologic complications of pediatric human immunodeficiency virus: Implications for clinical practice and management challenges in the african setting. *Semin. Pediatr. Neurol.* 2014, 21, 3–11. [CrossRef] [PubMed]
30. Foster, S.B.; Lu, M.; Glaze, D.G.; Reuben, J.M.; Harris, L.L.; Cohen, E.N.; Lee, B.N.; Zhao, E.; Paul, M.E.; Schwarzwald, H.; et al. Associations of cytokines, sleep patterns, and neurocognitive function in youth with HIV infection. *Clin. Immunol.* 2012, 144, 13–23. [CrossRef] [PubMed]
31. Hoare, J.; Westgarth-Taylor, J.; Fouche, J.P.; Spottiswoode, B.; Paul, R.; Thomas, K.; Stein, D.; Joska, J. A diffusion tensor imaging and neuropsychological study of prospective memory impairment in south african HIV positive individuals. *Metab. Brain Dis.* 2012, 27, 289–297. [CrossRef] [PubMed]
32. Facchini, S.A.; Harding, S.A.; Waldron, R.L. Human immunodeficiency virus-1 infection and multiple sclerosis-like illness in a child. *Pediatr. Neurol.* 2002, 26, 231–235. [CrossRef]
33. McGuire, J.L.; Gill, A.J.; Douglas, S.D.; Kolson, D.L.; group, C.H.A.-R.E.T.E.R. Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders. *J. Neurovirol.* 2015, 21, 439–448. [CrossRef] [PubMed]
34. Norgren, N.; Rosengren, L.; Stigbrand, T. Elevated neurofilament levels in neurological diseases. *Brain Res.* 2003, 987, 25–31. [CrossRef]
35. Jessen Krut, J; Mellberg, T; Price, R.W.; Hagberg, L.; Fuchs, D.; Rosengren, L.; Nilsson, S.; Zetterberg, H.; Gisslen, M. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. *PLoS ONE* 2014, 9, e8591. [CrossRef] [PubMed]
36. Peluso, M.J.; Meyerhoff, D.J.; Price, R.W.; Peterson, J.; Lee, E.; Young, A.C.; Walter, R.; Fuchs, D.; Brew, B.J.; Cinque, P.; et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. *J. Infect. Dis.* 2013, 207, 1703–1712. [CrossRef] [PubMed]
37. Abdulle, S.; Mellgren, A.; Brew, B.J.; Cinque, P.; Hagberg, L.; Price, R.W.; Rosengren, L.; Gisslen, M. Csf neurofilament protein (NFL)—A marker of active HIV-related neurodegeneration. J. Neurol. 2007, 254, 1026–1032. [CrossRef] [PubMed]

38. Carryl, H.; Swang, M.; Lawrence, J.; Curtis, K.; Kamboj, H.; Van Rompay, K.K.; De Paris, K.; Burke, M.W. Of mice and monkeys: Can animal models be utilized to study neurological consequences of pediatric HIV-1 infection? ACS Chem. Neurosci. 2015, 6, 1276–1289. [CrossRef] [PubMed]

39. Bieniasz, P.D.; Cullen, B.R. Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J. Virol. 2000, 74, 9868–9877. [CrossRef] [PubMed]

40. Fitting, S.; Booze, R.M.; Mactutus, C.F. Neonatal intrahippocampal injection of the HIV-1 proteins GP120 and tat: Differential effects on behavior and the relationship to stereological hippocampal measures. Brain Res. 2008, 1232, 139–154. [CrossRef] [PubMed]

41. Moran, L.M.; Fitting, S.; Booze, R.M.; Webb, K.M.; Mactutus, C.F. Neonatal intrahippocampal HIV-1 protein Tat(1-86) injection: Neurobehavioral alterations in the absence of increased inflammatory cytokine activation. Int. J. Dev. Neurosci. 2014, 38, 195–203. [CrossRef] [PubMed]

42. Fitting, S.; Booze, R.M.; Hasselrot, U.; Mactutus, C.F. Dose-dependent long-term effects of tat in the rat hippocampal formation: A design-based stereological study. Hippocampus 2010, 20, 469–480. [CrossRef] [PubMed]

43. Hill, J.M.; Mervis, R.F.; Avidor, R.; Moody, T.W.; Brenneman, D.E. Hiv envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res. 1993, 603, 222–233. [CrossRef] [PubMed]

44. Fitting, S.; Booze, R.M.; Mactutus, C.F. Neonatal intrahippocampal gp120 injection: An examination early in development. Neurotoxicology 2007, 28, 101–107. [CrossRef] [PubMed]

45. Ensoi, B.; Buonaguro, L.; Barillari, G.; Fiorelli, V.; Gendelman, R.; Morgan, R.A.; Wingfield, P.; Gallo, R.C. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 tat protein on cell growth and viral transactivation. J. Virol. 1993, 67, 277–287. [PubMed]

46. Clements, J.E.; Mankowski, J.L.; Gama, L.; Zink, M.C. The accelerated simian immunodeficiency virus macaque model of human immunodeficiency virus-associated neurological disease: From mechanism to treatment. J. Neurovirol. 2008, 14, 309–317. [CrossRef] [PubMed]

47. Abel, K. The rhesus macaque pediatric siv infection model—A valuable tool in understanding infant hiv-1 pathogenesis and for designing pediatric HIV-1 prevention strategies. Curr. HIV Res. 2009, 7, 2–11. [CrossRef] [PubMed]

48. Worlein, J.M.; Leigh, J.; Larsen, K.; Kinman, L.; Schmidt, A.; Ochs, H.; Ho, R.J. Cognitive and motor deficits associated with HIV-2(287) infection in infant pigtailed macaques: A nonhuman primate model of pediatric neuro-aids. J. Neurol. 2005, 11, 34–45. [CrossRef] [PubMed]

49. Curtis, K.; Rollins, M.; Carryl, H.; Bradshaw, K.; Van Rompay, K.K.; Abel, K.; Burke, M.W. Reduction of pyramidal and immature hippocampal neurons in pediatric simian immunodeficiency virus infection. Neuroreport 2014, 25, 973–978. [CrossRef] [PubMed]

50. Jensen, K.; Nabi, R.; Van Rompay, K.K.; Robichaux, S.; Lifson, J.D.; Piatak, M., Jr.; Jacobs, W.R., Jr.; Fennelly, G.; Canfield, D.; Mollan, K.R.; et al. Vaccine-elicited mucosal and systemic antibody responses are associated with reduced simian immunodeficiency viremia in infant rhesus macaques. J. Virol. 2016, 90, 7285–7302. [CrossRef] [PubMed]

51. Jensen, K.; Dela Pena-Ponce, M.G.; Piatak, M., Jr.; Shoemaker, R.; Oswald, K.; Jacobs, W.R., Jr.; Fennelly, G.; Lucero, C.; Mollan, K.R.; Hudgens, M.G.; et al. Balancing trained immunity with persistent immune activation and the risk of simian immunodeficiency virus infection in infant macaques vaccinated with attenuated mycobacterium tuberculosis or mycobacterium bovis bcg vaccine. Clin. Vaccine Immunol. 2017, 24, e00360-16. [CrossRef] [PubMed]

52. Jensen, K.; Ranganathan, U.D.; Van Rompay, K.K.; Canfield, D.R.; Khan, I.; Ravindran, R.; Luciw, P.A.; Jacobs, W.R., Jr.; Fennelly, G.; Larsen, M.H.; et al. A recombinant attenuated mycobacterium tuberculosis vaccine strain is safe in immunosuppressed simian immunodeficiency virus-infected infant macaques. Clin. Vaccine Immunol. 2012, 19, 1170–1181. [CrossRef] [PubMed]

53. Jensen, K.; Pena, M.G.; Wilson, R.L.; Ranganathan, U.D.; Jacobs, W.R., Jr.; Fennelly, G.; Larsen, M.; Van Rompay, K.K.; Kozlowski, P.A.; Abel, K. A neonatal oral mycobacterium tuberculosis-siv prime/intramuscular mva-siv boost combination vaccine induces both siv and mtb-specific immune responses in infant macaques. Trials Vaccinol. 2013, 2, 53–63. [CrossRef] [PubMed]
54. Burke, M.W.; Pito, M.; Ervin, F.R.; Palmour, R.M. Hippocampal neuron populations are reduced in vervet monkeys with fetal alcohol exposure. *Dev. Psychobiol.* **2015**, *57*, 470–485. [CrossRef] [PubMed]

55. Jabes, A.; Lavenex, P.B.; Amaral, D.G.; Lavenex, P. Postnatal development of the hippocampal formation: A stereological study in macaque monkeys. *J. Comp. Neurol.* **2011**, *519*, 1051–1070. [CrossRef] [PubMed]

56. Cline, A.N.; Bess, J.W.; Piatak, M., Jr.; Lifson, J.D. Highly sensitive siv plasma viral load assay: Practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for aids. *J. Med. Primatol.* **2005**, *34*, 303–312. [CrossRef] [PubMed]

57. Smith, S.M.; Holland, B.; Russo, C.; Dailey, P.J.; Marx, P.A.; Connor, R.I. Retrospective analysis of viral load and siv antibody responses in rhesus macaques infected with pathogenic siv: Predictive value for disease progression. *AIDS Res. Hum. Retrovir.* **1999**, *15*, 1691–1701. [CrossRef] [PubMed]

58. Watson, A.; Ranchalis, J.; Travis, B.; McClure, J.; Sutton, W.; Johnson, P.R.; Hu, S.L.; Haigwood, N.L. Plasma viremia in macaques infected with simian immunodeficiency virus: Plasma viral load early in infection predicts survival. *J. Virol.* **1997**, *71*, 284–290. [PubMed]

59. Phillips, N.; Amos, T.; Kuo, C.; Hoare, J.; Ipser, J.; Thomas, K.G.; Stein, D.J. HIV-associated cognitive impairment in perinatally infected children: A meta-analysis. *Pediatrics* **2016**, *138*. [CrossRef] [PubMed]

60. Li, M.; Long, C.; Yang, L. Hippocampal-prefrontal circuit and disrupted functional connectivity in psychiatric and neurodegenerative disorders. *Biomed. Res. Int.* **2015**, *2015*, 810548. [CrossRef] [PubMed]

61. Lavenex, P.; Amaral, D.G. Hippocampal-neocortical interaction: A hierarchy of associativity. *Hippocampus* **2000**, *10*, 420–430. [CrossRef]

62. Friedman, H.R.; Goldman-Rakic, P.S. Activation of the hippocampus and dentate gyrus by working-memory: A 2-deoxyglucose study of behaving rhesus monkeys. *J. Neurosci.* **1988**, *8*, 4693–4706. [PubMed]

63. Nagarajan, R.; Sarma, M.K.; Thomas, M.A.; Chang, L.; Natha, U.; Wright, M.; Hayes, J.; Nielsen-Saines, K.; Michalik, D.E.; Deville, J.; et al. Neuropsychological function and cerebral metabolites in hiv-infected youth. *J. Neuroimmune Pharmacol.* **2012**, *7*, 981–990. [CrossRef] [PubMed]

64. Luthert, P.J.; Montgomery, M.M.; Dean, A.F.; Cook, R.W.; Baskerville, A.; Lantos, P.L. Hippocampal neuronal atrophy occurs in rhesus macaques following infection with simian immunodeficiency virus. *Neuropathol. Appl. Neurobiol.* **1995**, *21*, 529–534. [CrossRef]

65. Spruston, N. Pyramidal neurons: Dendritic structure and synaptic integration. *Nat. Rev. Neurosci.* **2008**, *9*, 206–221. [CrossRef] [PubMed]

66. Abrams, E.J.; Weedon, J.; Steketeet, R.W.; Lambert, G.; Bamji, M.; Brown, T.; Kalish, M.L.; Schoenbaum, E.E.; Thomas, P.A.; Thea, D.M. Association of human immunodeficiency virus (HIV) load early in life with disease progression among hiv-infected infants. New york city perinatal hiv transmission collaborative study group. *J. Infect. Dis.* **1998**, *178*, 101–108. [CrossRef] [PubMed]

67. Shearer, W.T.; Quinn, T.C.; LaRussa, P.; Lew, J.F.; Mofenson, L.; Almy, S.; Rich, K.; Handelsman, E.; Diaz, C.; Pagano, M.; et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and infants transmission study group. *N. Engl. J. Med.* **1997**, *336*, 1337–1342. [CrossRef] [PubMed]

68. Marthas, M.L.; van Rompoy, K.K.; Otsyula, M.; Miller, C.J.; Canfield, D.R.; Pedersen, N.C.; McChesney, M.B. Viral factors determine progression to aids in simian immunodeficiency virus-infected newborn rhesus macaques. *J. Virol.* **1995**, *69*, 4198–4205. [PubMed]

69. Van Rompoy, K.K.; Singh, R.P.; Brignolo, L.L.; Lawson, J.R.; Schmidt, K.A.; Pahar, B.; Canfield, D.R.; Tarara, R.P.; Sodora, D.L.; Bischofberger, N.; et al. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters. *J. Acquir. Immune Defic. Syndr.* **2004**, *36*, 900–914. [CrossRef] [PubMed]

70. Kovalevich, J.; Langford, D. Neuronal toxicity in hiv cns disease. *Future Virol.* **2012**, *7*, 687–698. [CrossRef] [PubMed]

71. Ellis, R.; Langford, D.; Masilah, E. HIV and antiretroviral therapy in the brain: Neuronal injury and repair. *Nat. Rev. Neurosci.* **2007**, *8*, 33–44. [CrossRef] [PubMed]

72. Nath, A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of hiv dementia. *J. Infect. Dis.* **2002**, *186*, S193–S198. [CrossRef] [PubMed]

73. Hong, S.; Banks, W.A. Role of the immune system in hiv-associated neuroinflammation and neurocognitive implications. *Brain Behav. Immun.* **2015**, *45*, 1–12. [CrossRef] [PubMed]
74. Richards, M.H.; Narasipura, S.D.; Kim, S.; Seaton, M.S.; Lutgen, V.; Al-Harthi, L. Dynamic interaction between astrocytes and infiltrating pbmcs in context of neuroaids. Glia 2015, 63, 441–451. [CrossRef] [PubMed]

75. Zayyad, Z.; Spudich, S. Neuropathogenesis of hiv: From initial neuroinvasion to HIV-associated neurocognitive disorder (hand). Curr. HIV/AIDS Rep. 2015, 12, 16–24. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).